Eleni Andreopoulou, ASCO 2018 – Advances in molecular therapy in triple-negative breast cancer

Significant advancements in breast cancer research emerged from ESMO 2023. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston). In this interview, Dr. Tolaney highlights some of the most valuable data including those from the KEYNOTE-756 (NCT03725059), Checkmate-7FL (NCT04109066), TOPION-Breast01 (NCT05104866) and monarchE (NCT03155997) breast […]

The final results of the phase 3, TULIP trial (NCT03262935), which compared trastuzumab duocarmazine (T-Duo) with physician’s choice of therapy in previously treated HER2-positive metastatic breast cancer, were presented at ESMO 2023.  Dr. Philippe Aftimos, the study investigator from the Institute Jules Bordet in Belgium, presented the results at the conference and then discussed them […]

The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]